Paul Sabatier University, Dental Faculty, Department of Biomaterials, Anatomical Sciences and Radiology, Toulouse University Hospital, Toulouse, France; STROMALab, University of Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France.
Paul Sabatier University, Dental Faculty, Department of Biomaterials, Anatomical Sciences and Radiology, Toulouse University Hospital, Toulouse, France.
Dent Mater. 2017 May;33(5):e212-e220. doi: 10.1016/j.dental.2017.01.019. Epub 2017 Feb 21.
In-vitro experiments on ormocers (ORganically MOdified CERamics) have provided controversial results. Consequently, the objectives of this meta-analysis were to (1) compare clinical performances of first generation ormocers versus conventional composite restorations, (2) explore the influence of various clinical factors and the impact of the quality of studies on published results.
The following databases were explored until 2017/01/08: Ovid MEDLINE In-Process, Pubmed, CENTRAL, HTA, DARE, LILACS and Google Scholar. Studies of more than two years with quantitative comparisons between ormocers and control groups were selected. Outcome was the failure of a restoration (need to repair, remove or replace). Multivariate random-effects Poisson's regression was used to obtain a summary estimate.
75% of the 8 included trials concerned Class I/II restorations. Although non-significant, the global failures were higher for ormocers (0.22 [-0.16; 0.61]). For Class I/II restorations, a significantly higher sensitivity was observed for ormocer-based materials compared to other composites (0.75 [0.01; 1.50]). An increase of the number of restorations per patient was associated with higher marginal adaptation failures for ormocers in Class I/II obturations (0.59 [0.11; 1.08]).
This study did not identify clear advantages of using the first generation of ormocer-based fillings rather than conventional composites. Given the recent development of new, dimethacrylate-diluent-free ormocer matrices, potentially more stable and resistant, new randomized clinical trials should be developed comparing this new family of pure ormocers with current composites.
关于有机改性陶瓷(ORMOCER)的体外实验结果存在争议。因此,本荟萃分析的目的是:(1)比较第一代有机改性陶瓷与传统复合树脂修复体的临床性能;(2)探讨各种临床因素的影响及研究质量对发表结果的影响。
检索了截至 2017 年 1 月 8 日的以下数据库:Ovid MEDLINE In-Process、PubMed、CENTRAL、HTA、DARE、LILACS 和 Google Scholar。选择了超过两年且对有机改性陶瓷和对照组进行定量比较的研究。结果为修复体失败(需要修复、去除或更换)。采用多变量随机效应泊松回归获得综合估计值。
8 项纳入试验中有 75%涉及 I/II 类修复体。尽管无统计学意义,但有机改性陶瓷的总体失败率更高(0.22 [0.16; 0.61])。对于 I/II 类修复体,与其他复合材料相比,基于有机改性陶瓷的材料具有更高的敏感性(0.75 [0.01; 1.50])。每例患者修复体数量的增加与 I/II 类封闭中有机改性陶瓷的边缘适应性失败增加相关(0.59 [0.11; 1.08])。
本研究未发现使用第一代有机改性陶瓷填充材料而非传统复合材料的明显优势。鉴于新型、无二甲基丙烯酸酯稀释剂的有机改性陶瓷基质的最新发展,可能具有更稳定和更强的性能,应开发新的随机临床试验,比较这种新型纯有机改性陶瓷与当前的复合材料。